Litcius/Paper detail

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Francesca Palandri, Giuseppe A. Palumbo, Elena Maria Elli, Nicola Polverelli, Giulia Benevolo, Bruno Martino, Elisabetta Abruzzese, Mario Tiribelli, Alessia Tieghi, Roberto Latagliata, Francesco Cavazzini, Micaela Bergamaschi, Gianni Binotto, Monica Crugnola, Alessandro Isidori, Giovanni Caocci, Florian H. Heidel, Novella Pugliese, Costanza Bosi, Daniela Bartoletti, Giuseppe Auteri, Daniele Cattaneo, Luigi Scaffidi, Malgorzata Monica Trawinska, Rossella Stella, F Ciantia, Fabrizio Pane, Antonio Cuneo, Mauro Krampera, Gianpietro Semenzato, Roberto M. Lemoli, Alessandra Iurlo, Nicola Vianelli, Michèle Cavo, Massimo Breccia, Massimiliano Bonifacio

2021Blood Cancer Journal75 citationsDOIOpen Access PDF

Abstract

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Topics & Concepts

RuxolitinibMyelofibrosisDiscontinuationMedicineIncidence (geometry)Internal medicinePediatricsBone marrowPhysicsOpticsMyeloproliferative Neoplasms: Diagnosis and TreatmentEosinophilic Disorders and SyndromesChronic Myeloid Leukemia Treatments
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis | Litcius